Additional Study Information: The purpose of this study is to see if the investigational drug MPT-0118 is effective in treating people with cancer. This is the first time the study drug, MPT-0118, will be given to humans. MPT-0118 will be given alone (monotherapy) and in combination with Keytruda (pembrolizumab). Pembrolizumab is approved by the FDA to treat certain types of cancer. MPT-0118 and Pembrolizumab are called immunotherapies, which are designed to activate your immune system to try to kill cancer cells. Cancers may include bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer, head and neck/oral cancers, kidney cancer, lung cancer, melanoma, pancreatic cancer, and prostate cancer.